GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access manufacturer-sponsored savings at t

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious disease of the liver.Wegovy can be used for patients suffering from noncirrhotic metabolic dysfunction-associated steatohepatitis,

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro which launched in the country eight months ago.

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

Key Takeaways Wegovy has received U.S. Food and Administration approval to treat MASH, a serious form of fatty liver diseaseAbout 14.9 million U.S. adults, or 6% of the population, have MASHWegovy is the first and only GLP-1 treatment approved for this condition WEDNESDAY,

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as MASH and severe fibrosis.